Flortaucipir F 18

Drug Profile

Flortaucipir F 18

Alternative Names: 18F-AV-1451; [18F] T 807; [3H]AV 1451; [F-18]T807; F-18-AV-1451; Fluorine 18 AV 1451; T807

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Siemens Medical Solutions
  • Developer Avid Radiopharmaceuticals; Northwestern University; University of Pennsylvania
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Brain injuries; Cognition disorders; Dementia; Depressive disorders; Neurodegenerative disorders; Progressive supranuclear palsy
  • Phase I Aphasia

Most Recent Events

  • 22 Sep 2017 Washington University School of Medicine initiates enrolment in a phase II trial for Alzheimer's disease (Diagnosis) in USA (NCT03287765)
  • 28 Aug 2017 Avid Radiopharmaceuticals completes a phase II follow up study in Alzheimer's disease (Diagnosis) in USA (NCT02795780)
  • 28 Jul 2017 Avid Radiopharmaceuticals completes a phase II/III trial (Diagnosis, In adults, In the elderly) for Alzheimer's disease in USA (IV) (NCT02016560)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top